Low-dose serotherapy improves early immune reconstitution after cord blood transplantation for primary immunodeficiencies

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 2, 2014, Pages 243-249

  Lane, Jonathan P ^a,b   Evans, Philippa T G ^a   Nademi, Zohreh ^b   Barge, Dawn ^b   Jackson, Anthony ^c   Hambleton, Sophie ^a,b   Flood, Terry J ^b   Cant, Andrew J ^a,b   Abinun, Mario ^a,b   Slatter, Mary A ^a,b   Gennery, Andrew R ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c INSTITUTE OF HUMAN GENETICS   (United Kingdom)

Author keywords

Alemtuzumab; Cord blood transplantation; Immune reconstitution; Primary immunodeficiency; Serotherapy

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; TREOSULFAN;

ADOLESCENT; ADULT; ADVERSE OUTCOME; ARTICLE; CHILD; CLINICAL ARTICLE; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; ENGRAFTMENT; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOTHERAPY; LOW DRUG DOSE; MALE; MIDDLE AGED; MORTALITY; MYELOABLATIVE CONDITIONING; NEUTROPHIL; PNEUMOCYSTIS PNEUMONIA; PRESCHOOL CHILD; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SCHOOL CHILD; SEROTHERAPY; SURVIVAL; T LYMPHOCYTE; VIRUS INFECTION; YOUNG ADULT;

ALEMTUZUMAB; CORD BLOOD TRANSPLANTATION; IMMUNE RECONSTITUTION; PRIMARY IMMUNODEFICIENCY; SEROTHERAPY;

ADOLESCENT; ADULT; CHILD; CHIMERISM; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84893146830     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.11.005     Document Type: Article

References (33)

1. van der Burg M., Gennery A.R. Educational paper. The expanding clinical and immunological spectrum of severe combined immunodeficiency. Eur J Pediatr 2011, 170:561-571.
2. Antoine C., Muller S., Cant A., et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 2003, 361:553-560.
3. Gennery A.R., Slatter M.A., Grandin L., et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: Entering a new century, do we do better?. JAllergy Clin Immunol 2010, 126. 602-610.
4. Gennery A.R., Cant A.J. Cord blood stem cell transplantation in primary immune deficiencies. Curr Opin Allergy Clin Immunol 2007, 7:528-534.
5. Slatter M.A., Gennery A.R. Umbilical cord stem cell transplantation for primary immunodeficiencies. Expert Opin Biol Ther 2006, 6:555-565.
6. Bhattacharya A., Slatter M.A., Chapman C.E., et al. Single centre experience of umbilical cord stem cell transplantation for primary immunodeficiency. Bone Marrow Transplant 2005, 36:295-299.
7. de Heredia C.D., Ortega J.J., Diaz M., et al. Unrelated cord blood transplantation for severe combined immunodeficiency and other primary immunodeficiencies. Bone Marrow Transplan 2008, 41:627-633.
8. Frangoul H., Wang L., Harrell F.E., et al. Unrelated umbilical cord blood transplantation in children with immune deficiency: results of a multicenter study. Bone Marrow Transplant 2010, 45:283-288.
9. Knutsen A.P., Wall D.A. Umbilical cord blood transplantation in severeT-cell immunodeficiency disorders: Two-year experience. JClin Immunol 2000, 20:466-476.
10. Morio T., Atsuta Y., Tomizawa D., et al. Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan. Br J Haematol 2011, 154:363-372.
11. Knutsen A.P., Wall D.A. Kinetics of T-cell development of umbilical cord blood transplantation in severe T-cell immunodeficiency disorders. JAllergy Clin Immunol 1999, 103:823-832.
12. Chakraverty R., Orti G., Roughton M., et al. Impact of invivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood 2010, 116:3080-3088.
13. Dodero A., Carrabba M., Milani R., et al. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. Exp Hematol 2005, 33:920-927.
14. Myers G.D., Krance R.A., Weiss H., et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant 2005, 36:1001-1008.
15. Poire X., van Besien K. Alemtuzumab in allogeneic hematopoetic stem cell transplantation. Expert Opinion on Biological Therapy 2011, 11:1099-1111.
16. Shah A.J., Kapoor N., Crooks G.M., et al. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants. Biol Blood Marrow Transplant 2007, 13:584-593.
17. Chakrabarti S., Mackinnon S., Chopra R., et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002, 99:4357-4363.
18. Juliusson G., Theorin N., Karlsson K., et al. Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival. Bone Marrow Transplant 2006, 37:503-510.
19. Landgren O., Gilbert E.S., Rizzo J.D., et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009, 113:4992-5001.
20. Bainton R.D., Byrne J.L., Davy B.J., Russell N.H. CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath. Blood 2002, 100:3843-3844.
21. Buyck H.C., Prentice H.G.F., Griffiths P.D., Emery V.C. The risk of early and late CMV DNAemia associated with Campath use in stem cell transplant recipients. Bone Marrow Transplant 2010, 45:1212-1219.
22. Lamba R., Carrum G., Myers G.D., et al. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with alemtuzumab. Bone Marrow Transplant 2005, 36:797-802.
23. Avivi I., Chakrabarti S., Milligan D.W., et al. Incidence and outcome of Adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biol Blood Marrow Transplant 2004, 10:186-194.
24. Chakrabarti S., Mautner V., Osman H., et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002, 100:1619-1627.
25. Chakrabarti S., Avivi I., Mackinnon S., et al. Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. Br J Haematol 2002, 119:1125-1132.
26. Berrington J.E., Barge D., Fenton A.C., et al. Lymphocyte subsets in term and significantly preterm UK infants in the first year of life analysed bysingle platform flow cytometry. Clin Exp Immunol 2005, 140:289-292.
27. Steffens C.M., Managlia E.Z., Landay A., Al-Harthi L. Interleukin-7-treated naive T cells can be productively infected by T-cell-adapted and primary isolates of human immunodeficiency virus 1. Blood 2002, 99:3310-3318.
28. Gennery A.R., Cant A.J., Spickett G.P., et al. Effect of immunosuppression after cardiac transplantation in early childhood on antibody response to polysaccharide antigen. Lancet 1998, 351:1778-1781.
29. Routledge D., Jackson A., Bourn D., et al. Quantitative assessment of mixed chimerism in allogeneic stem cell transplant patients - A comparison of molecular genetic and cytogenetic approaches. JPediat Hematol Onc 2007, 29:428-431.
30. Komanduri K.V., John L.S.S., de Lima M., et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 2007, 110:4543-4551.
31. Morris E.C., Rebello P., Thomson K.J., et al. Pharmacokinetics of alemtuzumab used for invivo and invitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003, 102:404-406.
32. Chiesa R., Gilmour K., Qasim W., et al. Omission of invivo T-cell depletion promotes rapid expansion of naïve CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. Br J Haematol 2012, 156:656-666.
33. Talvensarri K., Clave E., Douay C., et al. Abroad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation. Blood 2002, 99:1458-1464.